Who invested in OMass Therapeutics?
OMass Therapeutics, a Biotech & Pharma startup from UK, raised €275 million in a Series C round announced on 16 October 2026. Investors: Bain Capital Life Sciences (lead), Forbion (lead), Novo Holdings (lead), Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, Syncona, Oxford Science Enterprises, GV, Northpond Ventures and Sanofi Ventures.
OMass Therapeutics
€275 millionSeries CBiotech & PharmaBain Capital Life SciencesleadForbionleadNovo HoldingsleadJanus Henderson InvestorsSV Health InvestorsJefferson Life SciencesSynconaOxford Science EnterprisesGVNorthpond VenturesSanofi Ventures
Questions founders ask
- Who invested in OMass Therapeutics?
- Bain Capital Life Sciences, Forbion, Novo Holdings, Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, Syncona, Oxford Science Enterprises, GV, Northpond Ventures and Sanofi Ventures invested in OMass Therapeutics's Series C round, announced on 16 October 2026 (source: eu-startups.com).
- Who led OMass Therapeutics's Series C round?
- Bain Capital Life Sciences, Forbion and Novo Holdings, according to eu-startups.com.
- How much did OMass Therapeutics raise?
- €275 million in its Series C round, as reported by eu-startups.com.
Raising next? See which investors fit your round.
In 30 minutes you'll know which funds matter for your round.
Get a demoRounds are read from public funding coverage and matched against our investor database. Every line links to the article it came from — that article, not this page, is the source. Amounts are quoted exactly as the article stated them; we do not convert currencies. Individual angel investors named in an article are not listed here.
Something wrong? Tell us what to correct and we will fix it. To be removed from Oka entirely, use /remove-me.